Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

BACKGROUND: We assessed the activity and toxicity of the XELBEVOCT regimen in patients with metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). Ancillary studies evaluated hypertension, proteinuria, and vascular endothelial growth factor (VEGF) polymorphisms in predictin...

Descripción completa

Detalles Bibliográficos
Autores principales: Berruti, Alfredo, Fazio, Nicola, Ferrero, Anna, Brizzi, Maria Pia, Volante, Marco, Nobili, Elisabetta, Tozzi, Lucia, Bodei, Lisa, Torta, Mirella, D’Avolio, Antonio, Priola, Adriano Massimiliano, Birocco, Nadia, Amoroso, Vito, Biasco, Guido, Papotti, Mauro, Dogliotti, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996907/
https://www.ncbi.nlm.nih.gov/pubmed/24628963
http://dx.doi.org/10.1186/1471-2407-14-184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996907/
https://www.ncbi.nlm.nih.gov/pubmed/24628963
http://dx.doi.org/10.1186/1471-2407-14-184

Ejemplares similares